Table 2. Response to induction chemotherapy according to PET/CT.
| Patient no. | Site | Clinical Staging | 18F-FDG (max SUV)–T | 18F-FDG (max SUV)—N | Response (WHO) | Response (mWHO) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Day 14 | Change (%) | Baseline | Day 14 | Change (%) | |||||
| 1 | oropharynx | IVA | 7.21 | 6.34 | -13 | 4.3 | 3.4 | -21 | yes | yes |
| 2 | oropharynx | IVA | 16.07 | 6.79 | -58 | 7.6 | 4.88 | -36 | no | no |
| 3 | oropharynx | IVA | 3.32 | 2.83 | -15 | 7.3 | 4.08 | -44 | yes | yes |
| 4 | oropharynx | IVA | 7 | 4.3 | -39 | 4.55 | 2.22 | -51 | no | no |
| 5 | hypopharynx | IVB | 13.7 | 6.43 | -53 | 5.56 | 5.81 | 4 | no | yes |
| 6 | oropharynx | IVA | 12.9 | 10.4 | -19 | 6.5 | 3.47 | -47 | yes | yes |
| 7 | Larynx | III | 9.97 | 4.76 | -53 | 0 | 0 | 0 | yes | yes |
| 8 | oropharynx | III | 6.52 | 4.91 | -25 | 0 | 0 | 0 | yes | yes |
| 9 | oropharynx | IVB | 6.95 | 5.07 | -27 | 4.14 | 3.47 | -16 | yes | yes |
| 10 | oropharynx | IVA | 9.19 | 5 | -46 | 9.29 | 5.8 | -38 | yes | yes |
| 11 | oropharynx | III | 12.27 | 4.9 | -60 | 6.11 | 3.1 | -49 | yes | yes |
| 12 | oropharynx | IVA | 14 | 5.9 | -58 | 7.5 | 0 | -100 | yes | yes |
| 13 | hypopharynx | IVA | 10.1 | 11 | 9 | 8.4 | 8.3 | -1 | yes | yes |
| 14 | hypopharynx | IVA | 12.8 | 5.5 | -57 | 5.2 | 3.6 | -31 | yes | yes |
| 15 | Larynx | IVA | 6.1 | 3.7 | -39 | 10 | 4.4 | -63 | yes | yes |
| 16 | oropharynx | IVA | 15.2 | 4.6 | -70 | 5.9 | 3.7 | -37 | yes | yes |
| 17 | oropharynx | IVA | 8.9 | 9.9 | 11 | 4.9 | 9.6 | 96 | yes | yes |
| 18 | oropharynx | IVA | 8.8 | 1.9 | -79 | 7.2 | 1.7 | -77 | yes | yes |
| 19 | oropharynx | III | 8.3 | 4.4 | -47 | 0 | 0 | 0 | yes | yes |
| 20 | Larynx | IVA | 7.9 | 0 | -100 | 17.1 | 6.6 | -61 | no | no |
| 21 | oropharynx | IVA | 9.8 | 8.9 | -9 | 6.9 | 4.6 | -33 | yes | yes |
| 22 | oropharynx | IVA | 6.9 | 6.9 | 0 | 9 | 6.8 | -24 | no | yes |
| 23 | oropharynx | IVA | 5.9 | 3.8 | -36 | 4.3 | 0 | -100 | yes | yes |
| 24 | oropharynx | IVA | 9.6 | 4.6 | -52 | 8 | 5.3 | -34 | yes | yes |
| 25 | oropharynx | IVA | 7 | 5.2 | -36 | 5.6 | 5.3 | -5 | no | yes |
| 26 | oropharynx | IVA | 2.8 | 0 | -100 | 3.3 | 4.5 | 36 | yes | yes |
| 27 | oropharynx | III | 7.7 | 4.1 | -47 | 6.7 | 0 | -100 | yes | yes |
| 28 | oropharynx | IVB | 17.2 | 11.5 | -33 | 4.6 | 5.7 | 24 | yes | yes |
| 29 | oropharynx | IVB | 8.2 | 0 | -100 | 0 | 0 | 0 | yes | yes |
| 30 | oropharynx | IVA | 6.9 | 0 | -100 | 4.3 | 4.2 | -2 | yes | yes |
| 31 | oropharynx | III | 3.7 | 2.8 | -24 | 8.5 | 3 | -65 | yes | yes |
| 32 | oropharynx | III | 7.3 | 4.4 | -40 | 6.2 | 2.7 | -56 | yes | yes |
| 33 | oropharynx | IVA | 14 | 4.5 | -68 | 14.4 | 5.9 | -59 | yes | yes |
| 34 | oropharynx | IVB | 5.8 | 3.9 | -33 | 2.2 | 2.9 | 32 | no | no |
| 35 | oropharynx | IVB | 8.2 | 0 | -100 | 13.9 | 8.5 | -38.8 | yes | yes |
| 36 | oropharynx | IVB | 9.3 | 5 | -46.2 | 9.7 | 5 | -48.45 | yes | yes |
| 37 | oropharynx | III | 6.3 | 0 | -100 | 2.8 | 3.6 | 28.57 | yes | yes |
| 38 | oropharynx | IVA | 6.1 | 0 | -100 | 6.3 | 2.4 | -60.65 | yes | yes |
| 39 | oropharynx | IVA | 13.9 | 7.7 | -44.6 | 9.5 | 5 | -47.36 | yes | yes |
| 40 | oropharynx | IVB | 5.3 | 0 | -100 | 5.4 | 0 | -100 | yes | yes |
| 41 | hypopharynx | III | 13.1 | 3.2 | -75.5 | 2 | 1.6 | -20 | yes | yes |
| 42 | Larynx | IVB | 5.3 | 3.6 | -32 | 9.8 | 7.5 | -23.4 | yes | yes |
| 43 | oropharynx | IVA | 9.3 | 6.3 | -32.2 | 3.3 | 6.3 | 96.8 | no | no |
| 44 | oropharynx | IVA | 4.4 | 0 | -100 | 6.7 | 0 | -100 | yes | yes |
| 45 | oropharynx | IVB | 4.7 | 5.2 | 10.6 | 3.7 | 2.9 | -21.6 | yes | yes |
| 46 | oropharynx | IVA | 4.7 | 3.2 | -31.9 | 6.5 | 4.3 | -33.8 | yes | yes |
| 47 | oropharynx | IVA | 5.8 | 3.2 | -44.8 | 3.4 | 2.3 | -32.3 | yes | yes |
Change in primary tumor and maximum standard uptake value (SUV) of regional lymph nodes after the first induction chemotherapy (IC), and WHO and mWHO criteria for each individual patient (after the second cycle of IC). N = 47.